Vera Therapeutics Inc (NASDAQ:VERA) has a beta value of 1.13 and has seen 5.9 million shares traded in the recent trading session. The company, currently valued at $1.92B, closed the recent trade at $30.11 per share which meant it gained $11.16 on the day or 58.89% during that session. The VERA stock price is -71.4% off its 52-week high price of $51.61 and 38.46% above the 52-week low of $18.53. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.15 million shares traded. The 3-month trading volume is 1.05 million shares.
The consensus among analysts is that Vera Therapeutics Inc (VERA) is Buy stock at the moment, with a recommendation rating of 1.14. 0 analysts rate the stock as a Sell, while 1 rate it as Overweight. 1 out of 5 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight.
Vera Therapeutics Inc (NASDAQ:VERA) trade information
Over the past 30 days, the shares of Vera Therapeutics Inc (NASDAQ:VERA) have changed 26.78%. Short interest in the company has seen 7.07 million shares shorted with days to cover at 6.17.
Wall Street analysts have a consensus price target for the stock at $34, which means that the shares’ value could jump 11.44% from the levels at last check today.. The projected low price target is $6.0 while the price target rests at a high of $38.0. In that case, then, we find that the latest price level in today’s session is -26.2% off the targeted high while a plunge would see the stock lose 80.07% from the levels at last check today..
Vera Therapeutics Inc (VERA) estimates and forecasts
The company’s shares have lost -36.56% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 4.49% over the past 5 years. Earnings growth for 2025 is a modest -20.52% while over the next 5 years, the company’s earnings are expected to increase by 11.13%.
VERA Dividends
Vera Therapeutics Inc is expected to release its next earnings report on 2025-May-05 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Vera Therapeutics Inc (NASDAQ:VERA)’s Major holders
Insiders own 5.16% of the company shares, while shares held by institutions stand at 108.80% with a share float percentage of 114.72%. Investors are also buoyed by the number of investors in a company, with Vera Therapeutics Inc having a total of 265.0 institutions that hold shares in the company. The top two institutional holders are AVORO CAPITAL ADVISORS LLC with over 4.31 million shares worth more than $155.92 million. As of 2024-06-30, AVORO CAPITAL ADVISORS LLC held 7.8745% of shares outstanding.
The other major institutional holder is PRICE T ROWE ASSOCIATES INC /MD/, with the holding of over 3.62 million shares as of 2024-06-30. The firm’s total holdings are worth over $130.98 million and represent 6.6147% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are T. Rowe Price New Horizons Fund, Inc. and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . As of Mar 31, 2025 , the former fund manager holds about 2.63% shares in the company for having 1.68 shares of worth $50.75 million while later fund manager owns 1.5 shares of worth $45.4 million as of Mar 31, 2025 , which makes it owner of about 2.35% of company’s outstanding stock.
